• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,095
79
60
57
47

COUNTRY

55
17
8
6
5

CATEGORIES

  • 82
  • 121
  • 66
  • 66
  • 36
  • 37
  • 12
  • 11
  • 12
  • 18

PRICE

548
813
1,673
2,603

PUBLISHED

133
229
684
2,603

PRODUCT TYPE

2,454
74
62
12
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE

Lymphoblastic Lymphoma - Pipeline Review, H1 2013

Lymphoblastic Lymphoma - Pipeline Review, H1 2013 Summary 'Lymphoblastic Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022 Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men...

June 2013
FROM

Halaven ( Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Halaven ( Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - Japan Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

Abraxane (Non-Small Cell Lung Cancer) -Forecast and Market Analysis to 2022

Abraxane (Non-Small Cell Lung Cancer) -Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

Ramucirumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Ramucirumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Italy Drug Forecast and Market Analysis to 2022

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women Historically, the treatment paradigm has centered around chemotherapy However, the...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - Germany Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

Alimta (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Alimta (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women....

June 2013
FROM

Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013

Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013 Summary 'Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - US Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

Ganetespib (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Ganetespib (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

Nintedanib (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Nintedanib (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

Yervoy (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Yervoy (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women....

June 2013
FROM

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2013

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2013 Summary 'Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2013', provides an overview of the indication’s...

June 2013
FROM

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2013

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2013 Summary 'Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

June 2013
FROM

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2013

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2013 Summary 'Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

June 2013
FROM

Rhabdomyosarcoma - Pipeline Review, H1 2013

Rhabdomyosarcoma - Pipeline Review, H1 2013 Summary 'Rhabdomyosarcoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

June 2013
FROM
Loading Indicator

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)